Felix E. de Jongh

3.7k total citations · 1 hit paper
34 papers, 2.1k citations indexed

About

Felix E. de Jongh is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Pathology and Forensic Medicine. According to data from OpenAlex, Felix E. de Jongh has authored 34 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Oncology, 10 papers in Pulmonary and Respiratory Medicine and 8 papers in Pathology and Forensic Medicine. Recurrent topics in Felix E. de Jongh's work include Cancer Treatment and Pharmacology (11 papers), Advanced Breast Cancer Therapies (5 papers) and Chemotherapy-induced organ toxicity mitigation (5 papers). Felix E. de Jongh is often cited by papers focused on Cancer Treatment and Pharmacology (11 papers), Advanced Breast Cancer Therapies (5 papers) and Chemotherapy-induced organ toxicity mitigation (5 papers). Felix E. de Jongh collaborates with scholars based in Netherlands, Belgium and United States. Felix E. de Jongh's co-authors include Harry L.A. Janssen, Robert A. de Man, M. van Blankenstein, Solko W. Schalm, Wim C.J. Hop, Jaap Verweij, E. Maartense, Gϋnter von Minckwitz, Sibylle Loibl and Tanja Čufer and has published in prestigious journals such as Journal of Clinical Oncology, Gastroenterology and British Journal of Cancer.

In The Last Decade

Felix E. de Jongh

34 papers receiving 2.1k citations

Hit Papers

Trastuzumab Beyond Progression in Human Epidermal Growth ... 2009 2026 2014 2020 2009 100 200 300 400 500
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Trastuzumab Beyond Progression in Human Epidermal Growth Factor Receptor 2–Positive Advanced Breast Cancer: A German Breast Group 26/Breast International Group 03-05 Study
    2009 504 citations Gϋnter von Minckwitz, Marcus Schmidt et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Felix E. de Jongh Netherlands 22 1.2k 448 385 355 347 34 2.1k
Stanislas Ropert France 26 1.1k 0.9× 757 1.7× 296 0.8× 299 0.8× 287 0.8× 67 2.5k
Gregory D. Leonard United States 13 1.4k 1.1× 235 0.5× 286 0.7× 173 0.5× 221 0.6× 30 2.0k
Alessandro Passardi Italy 23 1.5k 1.2× 488 1.1× 681 1.8× 233 0.7× 213 0.6× 138 2.2k
Kyung Hwan Kim South Korea 26 994 0.8× 485 1.1× 326 0.8× 153 0.4× 120 0.3× 95 2.2k
Yu‐Yun Shao Taiwan 29 968 0.8× 470 1.0× 535 1.4× 439 1.2× 989 2.9× 146 2.4k
Cristina Grávalos Spain 23 1.7k 1.4× 960 2.1× 319 0.8× 109 0.3× 165 0.5× 81 2.3k
Călin Cainap Romania 18 376 0.3× 257 0.6× 356 0.9× 228 0.6× 450 1.3× 63 1.5k
Muhammad Wasif Saif United States 25 1.7k 1.4× 639 1.4× 222 0.6× 208 0.6× 180 0.5× 129 2.7k
Yohei Masugi Japan 31 1.1k 0.9× 677 1.5× 617 1.6× 614 1.7× 478 1.4× 127 2.9k
S.M.M. Basso Italy 23 634 0.5× 355 0.8× 409 1.1× 150 0.4× 176 0.5× 106 2.0k

Countries citing papers authored by Felix E. de Jongh

Since Specialization
Citations

This map shows the geographic impact of Felix E. de Jongh's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Felix E. de Jongh with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Felix E. de Jongh more than expected).

Fields of papers citing papers by Felix E. de Jongh

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Felix E. de Jongh. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Felix E. de Jongh. The network helps show where Felix E. de Jongh may publish in the future.

Co-authorship network of co-authors of Felix E. de Jongh

This figure shows the co-authorship network connecting the top 25 collaborators of Felix E. de Jongh. A scholar is included among the top collaborators of Felix E. de Jongh based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Felix E. de Jongh. Felix E. de Jongh is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Vitale, Silvia Rita, Anieta M. Sieuwerts, Nick Beije, et al.. (2018). An Optimized Workflow to Evaluate Estrogen Receptor Gene Mutations in Small Amounts of Cell-Free DNA. Journal of Molecular Diagnostics. 21(1). 123–137. 14 indexed citations
2.
Elias, Sjoerd G., Harm van Tinteren, Miangela M. Laclé, et al.. (2017). Maintenance treatment with capecitabine and bevacizumab versus observation in metastatic colorectal cancer: updated results and molecular subgroup analyses of the phase 3 CAIRO3 study. Annals of Oncology. 28(9). 2128–2134. 56 indexed citations
3.
Meijer, M., et al.. (2016). Lethal acute liver failure in a patient treated with sunitinib. BMJ Case Reports. 2016. bcr2015213624–bcr2015213624. 12 indexed citations
4.
Beije, Nick, Wendy Onstenk, Jaco Kraan, et al.. (2016). Prognostic Impact of HER2 and ER Status of Circulating Tumor Cells in Metastatic Breast Cancer Patients with a HER2-Negative Primary Tumor. Neoplasia. 18(11). 647–653. 40 indexed citations
5.
Sieuwerts, Anieta M., Marcel Smid, Joan Bolt‐de Vries, et al.. (2016). An 8-gene mRNA expression profile in circulating tumor cells predicts response to aromatase inhibitors in metastatic breast cancer patients. BMC Cancer. 16(1). 123–123. 21 indexed citations
6.
Drooger, Jan C., et al.. (2015). Neutrophil-guided dosing of anthracycline–cyclophosphamide-containing chemotherapy in patients with breast cancer: a feasibility study. Medical Oncology. 32(4). 113–113. 5 indexed citations
7.
Mostert, Bianca, Anieta M. Sieuwerts, Jaco Kraan, et al.. (2014). Gene expression profiles in circulating tumor cells to predict prognosis in metastatic breast cancer patients. Annals of Oncology. 26(3). 510–516. 45 indexed citations
8.
9.
10.
Binkhorst, Lisette, Teun van Gelder, Walter J. Loos, et al.. (2012). Effects of CYP Induction by Rifampicin on Tamoxifen Exposure. Clinical Pharmacology & Therapeutics. 92(1). 62–67. 29 indexed citations
11.
Minckwitz, Gϋnter von, Kathrin Schwedler, Marcus Schmidt, et al.. (2011). Trastuzumab beyond progression: Overall survival analysis of the GBG 26/BIG 3-05 phase III study in HER2-positive breast cancer. European Journal of Cancer. 47(15). 2273–2281. 141 indexed citations
12.
Graan, Anne‐Joy M. de, Sebastiaan F. Teunissen, Filip De Vos, et al.. (2011). Dextromethorphan As a Phenotyping Test to Predict Endoxifen Exposure in Patients on Tamoxifen Treatment. Journal of Clinical Oncology. 29(24). 3240–3246. 42 indexed citations
13.
Konings, Inge R., et al.. (2010). The addition of pravastatin to chemotherapy in advanced gastric carcinoma: A randomised phase II trial. European Journal of Cancer. 46(18). 3200–3204. 59 indexed citations
14.
Minckwitz, Gϋnter von, C. Zielinski, Maike Schmidt, et al.. (2008). Capecitabine vs. capecitabine + trastuzumab in patients with HER2-positive metastatic breast cancer progressing during trastuzumab treatment: The TBP phase III study (GBG 26/BIG 3–05). Journal of Clinical Oncology. 26(15_suppl). 1025–1025. 52 indexed citations
15.
Jongh, Felix E. de, et al.. (2004). Population pharmacokinetics of cisplatin in adult cancer patients. Cancer Chemotherapy and Pharmacology. 54(2). 105–112. 40 indexed citations
16.
Steeghs, Neeltje, Felix E. de Jongh, Peter A.E. Sillevis Smitt, & Martin J. van den Bent. (2003). Cisplatin-induced encephalopathy and seizures. Anti-Cancer Drugs. 14(6). 443–446. 43 indexed citations
17.
Jongh, Felix E. de, Ruben N. van Veen, Ronald de Wit, et al.. (2003). Weekly high-dose cisplatin is a feasible treatment option: analysis on prognostic factors for toxicity in 400 patients. British Journal of Cancer. 88(8). 1199–1206. 214 indexed citations
18.
Jongh, Felix E. de, Ronald de Wit, Jaap Verweij, et al.. (2002). Dose-dense cisplatin/paclitaxel. European Journal of Cancer. 38(15). 2005–2013. 33 indexed citations
19.
Jongh, Felix E. de, Harry L.A. Janssen, Robert A. de Man, et al.. (1992). Survival and prognostic indicators in hepatitis B surface antigen-positive cirrhosis of the liver. Gastroenterology. 103(5). 1630–1635. 330 indexed citations
20.
Nix, G. A. J. J., et al.. (1991). Prognostic implications of the localization of carcinoma in the head of the pancreas.. PubMed. 86(8). 1027–32. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Stanislas Ropert Breakdown of academic impact, for papers by Gregory D. Leonard Breakdown of academic impact, for papers by Alessandro Passardi Breakdown of academic impact, for papers by Kyung Hwan Kim Breakdown of academic impact, for papers by Yu‐Yun Shao Breakdown of academic impact, for papers by Cristina Grávalos Breakdown of academic impact, for papers by Călin Cainap Breakdown of academic impact, for papers by Muhammad Wasif Saif Breakdown of academic impact, for papers by Yohei Masugi Breakdown of academic impact, for papers by S.M.M. Basso
Rankless by CCL
2026